Chinese English Japanese Germany Korea


다카바진 구조식 이미지
카스 번호:
포뮬러 무게:
MOL 파일:

다카바진 속성

끓는 점
315.57°C (rough estimate)
1.3206 (rough estimate)
1.7500 (estimate)
저장 조건
Slightly soluble in water and in anhydrous ethanol, practically insoluble in methylene chloride.
물리적 상태
산도 계수 (pKa)
pKa 4.42 (Uncertain)
Slightly soluble in water, DMSO and ethanol /n
CAS 데이터베이스
4342-03-4(CAS DataBase Reference)
Dacarbazine (4342-03-4)
  • 위험 및 안전 성명
  • 위험 및 사전주의 사항 (GHS)
위험품 표기 T,Xi,Xn
위험 카페고리 넘버 45-46-20/21/22-36/37/38
안전지침서 53-36/37/39-45-37/39-36-26
WGK 독일 3
RTECS 번호 NI3950000
HS 번호 29349990
유해 물질 데이터 4342-03-4(Hazardous Substances Data)
신호 어: Danger
유해·위험 문구:
암호 유해·위험 문구 위험 등급 범주 신호 어 그림 문자 P- 코드
H303 삼키면 유해할 수 있음 급성 독성 물질 - 경구 구분 5 P312
H311 피부와 접촉하면 유독함 급성 독성 물질 - 경피 구분 3 위험 P280, P302+P352, P312, P322, P361,P363, P405, P501
H315 피부에 자극을 일으킴 피부부식성 또는 자극성물질 구분 2 경고 P264, P280, P302+P352, P321,P332+P313, P362
H319 눈에 심한 자극을 일으킴 심한 눈 손상 또는 자극성 물질 구분 2A 경고 P264, P280, P305+P351+P338,P337+P313P
H332 흡입하면 유해함 급성 독성 물질 흡입 구분 4 경고 P261, P271, P304+P340, P312
H335 호흡 자극성을 일으킬 수 있음 특정 표적장기 독성 - 1회 노출;호흡기계 자극 구분 3 경고
H340 유전적인 결함을 일으킬 수 있음 (노출되어도 생식세포 유전독성을 일으키지 않는다는 결정적인 증거가 있는 노출경로가 있다면 노출경로 기재) 생식세포 변이원성 물질 구분 1A, 1B 위험
H350 암을 일으킬 수 있음 (노출되어도 암을 일으키지 않는다는 결정적인 증거가 있는 노출경로가 있다면 노출경로 기재) 발암성 물질 구분 1A, 1B 위험
P201 사용 전 취급 설명서를 확보하시오.
P261 분진·흄·가스·미스트·증기·...·스프레이의 흡입을 피하시오.
P280 보호장갑/보호의/보안경/안면보호구를 착용하시오.
P305+P351+P338 눈에 묻으면 몇 분간 물로 조심해서 씻으시오. 가능하면 콘택트렌즈를 제거하시오. 계속 씻으시오.
P405 밀봉하여 저장하시오.

다카바진 MSDS


다카바진 C화학적 특성, 용도, 생산

화학적 성질

Off-white Cryst

화학적 성질

Dacarbazine is a white to ivory-colored crystalline solid.


Used as an antineoplastic. Used in the treatment of malignant melanoma and sarcomas.




Dacarbazine is used as an antineoplastic for treatment of malignant melanoma and sarcomas.


ChEBI: A monocarboxylic acid amide that is 1H-imidazole-4-carboxamide which is substituted at position 5 by a 3,3-dimethyltriaz-1-en-1-yl group. It is used for the treatment of metastatic malignant melanoma, and in combination with other drugs or the treatment of Hodgkin's disease and soft-tissue sarcoma.


Dacarbazine (DTIC-Dome) is activated by photodecomposition and by enzymatic N-demethylation. Eventual formation of a methyl carbonium ion results in methylation of DNA and RNA and inhibition of nucleic acid and protein synthesis. As with other alkylating agents, cells in all phases of the cell cycle are susceptible to dacarbazine.
The plasma half-life of dacarbazine is biphasic, with a distribution phase of 19 minutes and an elimination phase of 5 hours. The drug is not appreciably protein bound, and it does not enter the central nervous system (CNS). Urinary excretion of unchanged drug is by renal tubular secretion. Dacarbazine metabolism and decomposition is complex.
Dacarbazine is the most active agent used in metastatic melanoma, producing a 20% remission rate. It is also combined with doxorubicin and other agents in the treatment of various sarcomas and Hodgkin’s disease.
Dacarbazine may cause severe nausea and vomiting. Leukopenia and thrombocytopenia occur 2 weeks after treatment, with recovery by 3 to 4 weeks. Less common is a flulike syndrome of fever, myalgias, and malaise. Alopecia and transient abnormalities in renal and hepatic function also have been reported.

일반 설명

Dacarbazine is available in 100- and 200-mg vials for IVadministration in the treatment of Hodgkin’s disease, malignantmelanoma, carcinoid cancer, neuroblastoma, andsoft tissue sarcoma. Resistance to dacarbazine has been primarilyattributed to enhanced activity of AGAT. The volumeof distribution exceeds the amount of water in thebody suggesting the compound distributes into body tissuespossibly the liver. The agent is not highly protein bound(20%) and is metabolized in the liver by CYP to give MTICand 4-amino-5-imidazole-carboxamide (AIC).Thedemethylation reaction is mediated by isozymes CYP1A1/2and CYP2E1. Elimination occurs via the urine with 40% to50% occurring as unchanged drug. Dose-limiting myelosuppressionpresents as both leucopenia and thrombocytopenia.Other adverse effects include nausea, vomiting,flulike symptoms, photosensitivity, and pain at the injectionsite.

일반 설명

White to ivory microcrystals or off-white crystalline solid.

공기와 물의 반응

Insoluble in water.

반응 프로필

Dacarbazine decomposes explosively at its melting point (250°C). Decomposes in the presence of light. Sensitive to oxidation.


Flash point data for Dacarbazine are not available. Dacarbazine is probably combustible.

Safety Profile

Confirmed carcinogen with experimental carcinogenic and tumorigenic data. Poison by intraperitoneal and parenteral routes. Moderately toxic by ingestion and intravenous routes. Experimental teratogenic effects. Human systemic effects by intravenous route: nausea or vomiting, leukopenia (reduced white blood cell count), and changes in dehydrogenase enzymatic activity. Mutation data reported. When heated to decomposition it emits toxic fumes of NOx.

잠재적 노출

Dacarbazine is used in cancer chemo- therapy. Dacarbazine is used as an antineoplastic agent in the treatment of certain skin cancers, and is occasionally used in the therapy of other neoplastic diseases which have become resistant to alternative Health professionals who handle this drug (for example, pharmacists, nurses, and physicians) may possibly be exposed during drug preparation, administration, or cleanup; however, the risks can be avoided through use of appropriate containment equipment and work practices .People receiving dacarbazine in treatment are also exposed.

Veterinary Drugs and Treatments

Dacarbazine has been used to treat relapsed canine lymphoma, soft tissue sarcomas and melanoma in dogs. In combination with doxorubicin, dacarbazine has been evaluated to treat dogs with relapsed lymphosarcoma. Ongoing studies evaluating various protocols are ongoing for this indication.

운송 방법

UN3249 Medicine, solid, toxic, n.o.s., Hazard Class: 6.1; Labels: 6.1-Poisonous materials.

비 호환성

ncompatible with oxidizers (chlorates, nitrates, peroxides, permanganates, perchlorates, chlorine, bromine, fluorine, etc.); contact may cause fires or explo- sions. Keep away from alkaline materials, strong bases, strong acids, oxoacids, and epoxides. Explosive decom- position reported @ 250℃ 255℃

폐기물 처리

It is inappropriate and possi- bly dangerous to the environment to dispose of expired or waste drugs and pharmaceuticals by flushing them down the toilet or discarding them to the trash. Household quanti- ties of expired or waste pharmaceuticals may be mixed with wet cat litter or coffee grounds, double-bagged in plastic, discard in trash. Larger quantities shall carefully take into consideration applicable DEA, EPA, and FDA regulations. If possible return the pharmaceutical to the manufacturer for proper disposal being careful to properly label and securely package the material. Alternatively, the waste pharmaceutical shall be labeled, securely packaged and transported by a state licensed medical waste contractor to dispose by burial in a licensed hazardous or toxic waste landfill or incinerator.

다카바진 준비 용품 및 원자재


준비 용품

다카바진 공급 업체

글로벌( 235)공급 업체
공급자 전화 팩스 이메일 국가 제품 수 이점
Henan DaKen Chemical CO.,LTD.
+86-371-55531817 CHINA 21792 58
Beijing Cooperate Pharmaceutical Co.,Ltd.
+86-10-60279497 +86(0)15646567669
+86-10-60279497 CHINA 1817 55
Henan Tianfu Chemical Co.,Ltd.
0371-55170693 CHINA 22631 55
020-81716319 CHINA 2543 55
Shanghai Zheyan Biotech Co., Ltd.
18017610038 CHINA 3623 58
Chemwill Asia Co.,Ltd.
86-21-51861608;;; CHINA 23978 58
Hubei xin bonus chemical co. LTD
027-59338440 CHINA 23048 58
86-18523575427 CHINA 47484 58
career henan chemical co
0086-371-86658258 CHINA 24509 58
Shenzhen Sendi Biotechnology Co.Ltd. 0755-23311925 18102838259
0755-23311925 CHINA 3194 55

다카바진 관련 검색:

Copyright 2019 © ChemicalBook. All rights reserved